An Enzymatically Active A Domain Is Required for Cholera-Like Enterotoxins To Induce a Long-Lived Blockade on the Induction of Oral Tolerance: New Method for Screening Mucosal Adjuvants
Open Access
- 1 December 2003
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (12) , 6899-6905
- https://doi.org/10.1128/iai.71.12.6850-6856.2003
Abstract
The cholera-like enterotoxins (CLETS), cholera toxin (CT) andEscherichia coliheat-labile toxin (LT), are powerful mucosal adjuvants. Here we show that these toxins also induce a long-lived blockade (of at least 6 months) on the induction of oral tolerance when they are coadministered with the antigen ovalbumin. Strikingly, only enzymatically active CLETS induced this blockade on the induction of oral tolerance. In this regard, the enzymatically inactive mutants of CT and LT, CTK63 and LTK63, and their recombinant B pentamers, rCTB and rLTB, failed to block the induction of oral tolerance, demonstrating a stringent requirement for an enzymatically active A domain in this phenomenon. Together with the results of other recent studies, these results indicate that the enzymatic activity of CLETS, most likely cyclic AMP elevation, is responsible for their adjuvant effects. The results of this study also indicate that measuring the ability of putative mucosal adjuvants to block the induction of oral tolerance may be a superior method for measuring mucosal adjuvanticity.Keywords
This publication has 35 references indexed in Scilit:
- Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxinVaccine, 2003
- Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunitVaccine, 1998
- A novel concept in mucosal adjuvanticity: The CTA1‐DD adjuvant is a B cell‐targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunitImmunology & Cell Biology, 1998
- Peripheral deletion of antigen-reactive T cells in oral toleranceNature, 1995
- Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of AutoantigensAnnual Review of Immunology, 1994
- Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.The Journal of Experimental Medicine, 1992
- Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTBVaccine, 1989
- Long‐Term Cholera Antitoxin Memory in the Gut can be Triggered to Antibody Formation Associated with Protection within Hours of an Oral Challenge ImmunizationScandinavian Journal of Immunology, 1987
- Size and Structure of the Cholera Toxin Molecule and Its SubunitsThe Journal of Infectious Diseases, 1976
- Cholera Toxin: Interaction of Subunits with Ganglioside G M1Science, 1974